Acucela Inc. and Otsuka Pharmaceutical Co., Ltd. Announce Phase IIa Clinical Results of Emixustat Hydrochloride (ACU-4429) in Patients with Geographic Atrophy (GA) Associated with Dry Age-Related Macular Degeneration (AMD) at Association for Research in V

Published: May 09, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Acucela Inc., a clinical-stage biotechnology company focused on developing therapies for sight-threatening diseases, and Otsuka Pharmaceutical Co., Ltd., (Otsuka) a Japan-based, “big venture” pharmaceutical company, today announced results from a recently completed phase IIa study of emixustat hydrochloride in patients with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD).

Help employers find you! Check out all the jobs and post your resume.

Back to news